Update in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by Shareholders Foundation
June 21 2016 - 9:50AM
The Shareholders Foundation, Inc. announces that a lawsuit is
pending in Massachusetts on behalf of certain purchasers of shares
of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) over alleged
Securities Laws Violations by Aegerion Pharmaceuticals.
Investors who purchased shares of Aegerion Pharmaceuticals, Inc.
(NASDAQ:AEGR) prior to April 2013 and continue to hold any of those
NASDAQ:AEGR shares have also certain options and should contact the
Shareholders Foundation at mail@shareholdersfoundation.com or
call +1(858) 779 - 1554.
In November 2013, news reports revealed that Aegerion
Pharmaceuticals, Inc. received an FDA Warning Letter in connection
with statements the Company's CEO made regarding JUXTAPID capsules,
during broadcast interviews on CNBC's television show, "Fast
Money," that aired on June 5, 2013, and October 31, 2013.
On January 9, 2014, Aegerion Pharmaceuticals, Inc. reported its
preliminary 2013 Net product sales, its outlook for 2014 and other
business updates. Among other things, Aegerion Pharmaceuticals,
Inc. announced that it has received a subpoena from the United
States Department of Justice, represented by the U.S. Attorney’s
Office in Boston, MA, requesting documents regarding the Company’s
marketing and sale of JUXTAPID in the U.S.
On January 15, 2014 a lawsuit was filed against Aegerion
Pharmaceuticals, Inc. over alleged securities laws violations. The
plaintiff claimed that the defendants made allegedly false and/or
misleading statements and/or failed to disclose to Aegerion
Pharmaceuticals, Inc. investors that Aegerion Pharmaceuticals, Inc.
marketed its drugs in violation of the FDCA, that as a result,
Aegerion Pharmaceuticals, Inc. faced heightened regulatory scrutiny
by the FDA and other governmental bodies, and that as a result of
the foregoing, Aegerion Pharmaceuticals Inc.'s statements were
allegedly materially false and misleading at all relevant times. In
August 2015 an amended complaint was filed.
Those who purchased shares of Aegerion Pharmaceuticals, Inc.
(NASDAQ:AEGR) prior to April 2013 and continue to hold any of those
NASDAQ:AEGR shares have also certain options and should contact the
Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio
legal monitoring and a settlement claim filing service, which does
research related to shareholder issues and informs investors of
securities class actions, settlements, judgments, and other legal
related news to the stock/financial market. The Shareholders
Foundation, Inc. is not a law firm. The information is provided as
a public service. It is not intended as legal advice and should not
be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)
Historical Stock Chart
From Jan 2024 to Jan 2025